[go: up one dir, main page]

GB0717101D0 - Tumour marker - Google Patents

Tumour marker

Info

Publication number
GB0717101D0
GB0717101D0 GBGB0717101.0A GB0717101A GB0717101D0 GB 0717101 D0 GB0717101 D0 GB 0717101D0 GB 0717101 A GB0717101 A GB 0717101A GB 0717101 D0 GB0717101 D0 GB 0717101D0
Authority
GB
United Kingdom
Prior art keywords
tumour marker
tumour
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0717101.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Priority to GBGB0717101.0A priority Critical patent/GB0717101D0/en
Publication of GB0717101D0 publication Critical patent/GB0717101D0/en
Priority to PCT/GB2008/002954 priority patent/WO2009030884A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0717101.0A 2007-09-03 2007-09-03 Tumour marker Ceased GB0717101D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0717101.0A GB0717101D0 (en) 2007-09-03 2007-09-03 Tumour marker
PCT/GB2008/002954 WO2009030884A2 (en) 2007-09-03 2008-09-01 Mannosylated butyrophilin tumour markers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0717101.0A GB0717101D0 (en) 2007-09-03 2007-09-03 Tumour marker

Publications (1)

Publication Number Publication Date
GB0717101D0 true GB0717101D0 (en) 2007-10-10

Family

ID=38617179

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0717101.0A Ceased GB0717101D0 (en) 2007-09-03 2007-09-03 Tumour marker

Country Status (2)

Country Link
GB (1) GB0717101D0 (en)
WO (1) WO2009030884A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031736A2 (en) * 2009-09-14 2011-03-17 The Rockefeller University Methods of identifying anti-inflammatory compounds
WO2015077844A1 (en) * 2013-11-29 2015-06-04 Csl Limited Method of treating cancer
CN105457024B (en) * 2014-10-13 2021-03-16 李小彦 Anti-butyrophilin-3 humanized antibody and use thereof
WO2016191305A1 (en) * 2015-05-22 2016-12-01 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
AU2016365318B2 (en) * 2015-12-02 2024-04-18 Board Of Regents, The University Of Texas System Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
JP7227007B2 (en) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド Antibodies specific for glycosylated BTLA (B- and T-lymphocyte-attenuating factor)
CA3065300A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
KR20250036941A (en) * 2017-05-31 2025-03-14 주식회사 에스티큐브앤컴퍼니 Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
EP3684795A1 (en) * 2017-09-21 2020-07-29 Imcheck Therapeutics SAS Antibodies having specificity for btn2 and uses thereof
US11098093B2 (en) 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
SG11202106895UA (en) 2019-01-07 2021-07-29 Shattuck Labs Inc Heterodimeric proteins for modulating gamma delta t cells
EP3696191A1 (en) * 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car t-cells for the treatment of cd1a-positive cancer
SG11202109932WA (en) * 2019-03-20 2021-10-28 Imcheck Therapeutics Sas Antibodies having specificity for btn2 and uses thereof
CN114746445A (en) * 2019-06-28 2022-07-12 墨尔本大学 Methods of inhibiting or activating γ δ T cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520251A (en) * 2004-11-22 2008-06-19 ワイス Methods and systems for prognosis and treatment of solid tumors

Also Published As

Publication number Publication date
WO2009030884A3 (en) 2009-06-04
WO2009030884A2 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
GB0717101D0 (en) Tumour marker
EP2079385A4 (en) Breast marker
PL2176664T3 (en) Ccr4 as cancer marker
ZA200907678B (en) Polynucleotide markers
HK1147684A1 (en) Targeted radiotherapy
GB0922437D0 (en) Hypoxia tumour markers
GB0707933D0 (en) Disease markers
EP2262951A4 (en) Tactile marker
GB0724412D0 (en) Marker
AU320442S (en) Marker
ZA201200888B (en) New tumor marker
GB0714573D0 (en) Marker gene
GB2477687B (en) X-ray marker
GB0908071D0 (en) Marker
GB0905964D0 (en) Marker
GB0707671D0 (en) Fiducial marker
GB0718496D0 (en) Markers
GB0815935D0 (en) Marker apparatus
GB0700550D0 (en) Phsphorescent marker device
GB0703654D0 (en) Sterimatic dose marker
GB0717319D0 (en) Photoluminescent marker
GB0714398D0 (en) Ground improvement
GB0701817D0 (en) Marker
GB0804417D0 (en) Markers
GB2436401B (en) Marker

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)